PCN29 ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMAVERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING
Abstract
Authors
U Munir Benedict B Borgman R Sandin U Harmenberg A Ulln P Sandstrm